Related Experiment Video

Updated: May 29, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer

Afshin Dowlati1

  • 1Division of Hematology/Oncology, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA. afshin.dowlati@case.edu

Clinical Lung Cancer
|September 3, 2011
PubMed

Insights

Bevacizumab shows promise in expanding antiangiogenic therapies for lung cancer. Ongoing trials investigate its safety and efficacy in diverse patient groups and earlier disease stages.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Antiangiogenic therapies, including bevacizumab, sunitinib, and sorafenib, are gaining traction in cancer treatment.
  • Bevacizumab's current approval is limited to advanced non-squamous non-small-cell lung cancer (NSCLC) with specific patient criteria, restricting its broader application.
  • The potential benefits of bevacizumab in lung cancer could be significantly expanded if its use is validated in wider patient populations and earlier disease stages.

Purpose of the Study:

  • To explore the potential of bevacizumab in broader clinical settings for lung cancer.
  • To evaluate the safety and efficacy of bevacizumab in patient subgroups previously excluded from trials, such as those with hemoptysis, brain metastases, or squamous cell histology.
  • To assess the utility of bevacizumab in locally advanced and early-stage lung cancer.

Main Methods:

  • Ongoing clinical trials are investigating the safety and efficacy of bevacizumab in various lung cancer contexts.
  • These trials include patient populations with specific comorbidities and different histological subtypes.
  • Research is also examining bevacizumab's role in earlier phases of lung cancer, from locally advanced to early-stage disease.

Main Results:

  • Results from numerous ongoing clinical trials are anticipated within the next 2-3 years.
  • A key challenge identified is the lack of a specific predictive biomarker for response to antiangiogenic agents like bevacizumab.
  • Research in small-cell lung cancer (SCLC), a highly angiogenic cancer, lags behind NSCLC in antiangiogenic therapy trials.

Conclusions:

  • Bevacizumab holds potential for expanded use in lung cancer beyond its current indications.
  • Further research and clinical trials are crucial to define its role in diverse patient populations and disease stages.
  • The development of predictive biomarkers and increased research in SCLC are essential for advancing antiangiogenic therapy in lung cancer.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...